Paragraf
has acquired
Cardea Bio

In a first for the graphene electronics industry, leading integrated device manufacturer Paragraf has acquired graphene biosensor market pioneer Cardea Bio to accelerate the mass production of a new generation of devices that will deliver real-time analysis in point-of-need tests in the agritech, healthcare and environmental monitoring spaces.

BPU™
real-time multiomics

Internet
of Biology

Scientific
Papers

Technology

We introduce a new paradigm in understanding how electronics and biology work together: the Biological Processing Unit, or BPU. Like a CPU or a GPU, a BPU is a type of microchip.

What makes the BPU distinct is the integration of biological material with graphene, silicon, and other electronics materials.

Platform

Cardea’s BPU™ platform consists of BPUs, hardware, software and wetware. The core of the BPU is made up of multiple Cardean Transistors™ - graphene-based biology-gated field-effect transistors.

A functionalized BPU feeds biosignals to the Gateway Reader, that obtains and distributes the digital signal output to the software, the Gateway Analyzer.

Partners

Our Commercial Partnerships are designed for those who are ready to hit the ground running with their Powered by Cardea™ service. Commercial partners gain access to our current suite of technology to provide the infrastructure for their assay services. As we develop more technology modules, they will become available to our Commercial Partners and used to expand and build their offerings.

Careers

We are as bold and intentional in our COMMITMENT to build a caring, employee-centric culture aswe are in our VISION to change the world with our BPU’s